Results 61 to 70 of about 4,418 (114)
Canine CD20 geneThe human CD20 antigen, a 35 kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
openaire
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Engineering CD20 CARs with a Twist
Cancer Immunology Research, 2023CD20 is highly expressed in several types of B-cell lymphoma and is an intuitive target for chimeric antigen receptor (CAR) T-cell therapy. However, with conventional approaches, it has been challenging to provide CD20 CAR designs that confer efficacy in preclinical models and in clinical trials.
Lukas Scheller, Michael Hudecek
openaire +2 more sources
Veterinary Immunology and Immunopathology, 2005
The human CD20 antigen, a 35kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
Rui, Kano +7 more
openaire +4 more sources
The human CD20 antigen, a 35kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
Rui, Kano +7 more
openaire +4 more sources
Blood, 2008
To the editor: The FMC7 antibody, originally described in 1981,[1][1] detects an antigen expressed on mature human B cells and is used in immunophenotypic analysis and differential diagnosis of lymphomas and leukemias. The identity of the FMC7 antigen was unclear for many years.
Julie P, Deans, Maria J, Polyak
openaire +2 more sources
To the editor: The FMC7 antibody, originally described in 1981,[1][1] detects an antigen expressed on mature human B cells and is used in immunophenotypic analysis and differential diagnosis of lymphomas and leukemias. The identity of the FMC7 antigen was unclear for many years.
Julie P, Deans, Maria J, Polyak
openaire +2 more sources
Immunotherapy with anti-CD20 compounds
Seminars in Cancer Biology, 2003The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic ...
openaire +2 more sources
Inhibitory FcγRIIb and CD20 internalization
Blood, 2014In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based ...
openaire +2 more sources